Roszkowski, K <br/><br/>
A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  Mar 2000 
 - 145-57 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0169-5002 
<br/><br/><label>Standard No.: </label>10.1016/s0169-5002(00)00094-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Area Under Curve<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Combined Modality Therapy<br/>Docetaxel<br/>Europe<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mexico<br/>Middle Aged<br/>Paclitaxel--administration & dosage<br/>Palliative Care<br/>Quality of Life<br/>Survival Analysis<br/>Taxoids<br/>United States